title: Enterovirus 71 vaccine: close but still far.
abstract: BACKGROUND
  Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field.
  
  
  METHODS
  Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed.
  
  
  RESULTS
  Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development.
  
  
  CONCLUSIONS
  The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.
authors.affiliation: School of Public Health, Sun Yat-sen University, Laboratory for Tropical Disease Control and Prevention, Guangdong Provincial Research Center for Severe Infectious Disease Prevention and Control Technology, Guangzhou 510080, China.
authors.forename: Dingmei
authors.initials: D
authors.lastname: Zhang
authors.forename: Jiayuan
authors.initials: J
authors.lastname: Lu
authors.forename: Jiahai
authors.initials: J
authors.lastname: Lu
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D029821:Enterovirus A, Human / Q000276:immunology*; D004769:Enterovirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D000939:Epitopes / Q000276:immunology; D006232:Hand, Foot and Mouth Disease / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000939:Epitopes; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
references.citation: Vaccine. 2002 Jun 7;20(19-20):2485-93
references.pmid: 12057603
references.citation: Vaccine. 2004 Sep 28;22(29-30):3858-64
references.pmid: 15364432
references.citation: Acta Virol. 2005;49(1):17-22
references.pmid: 15929394
references.citation: Vaccine. 2008 Jun 2;26(23):2882-9
references.pmid: 18450335
references.citation: Vaccine. 2006 Apr 5;24(15):2944-51
references.pmid: 16448730
references.citation: Pediatrics. 2007 Aug;120(2):e244-52
references.pmid: 17671037
references.citation: J Virol. 2008 Feb;82(4):1787-97
references.pmid: 18057246
references.citation: Microbes Infect. 2007 Sep;9(11):1299-306
references.pmid: 17890123
references.citation: Expert Rev Vaccines. 2009 Jan;8(1):35-41
references.pmid: 19093771
references.citation: Proc Natl Acad Sci U S A. 1987 Jun;84(12):4002-6
references.pmid: 3035560
references.citation: Arch Virol. 1982;71(3):217-27
references.pmid: 6285858
references.citation: Genet Vaccines Ther. 2003 Sep 16;1(1):2
references.pmid: 14606963
references.citation: Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10527-31
references.pmid: 1438241
references.citation: Biochem Biophys Res Commun. 2009 Dec 25;390(4):1126-8
references.pmid: 19799860
references.citation: Eur J Pediatr. 2008 Nov;167(11):1335-8
references.pmid: 18317803
references.citation: Vaccine. 2007 Jan 2;25(1):19-24
references.pmid: 16919374
references.citation: Arch Dis Child. 1980 Aug;55(8):583-8
references.pmid: 6254449
references.citation: J Infect Dis. 1974 Mar;129(3):304-9
references.pmid: 4361245
references.citation: Annu Rev Immunol. 2000;18:927-74
references.pmid: 10837079
references.citation: Virus Res. 2007 Apr;125(1):61-8
references.pmid: 17222936
references.citation: Jpn J Med Sci Biol. 1981 Jun;34(3):191-6
references.pmid: 6273621
references.citation: Clin Microbiol Rev. 1992 Jul;5(3):328-42
references.pmid: 1498769
references.citation: J Biotechnol. 2003 Apr 24;102(2):105-15
references.pmid: 12697387
references.citation: Vaccine. 2007 Nov 1;25(44):7664-73
references.pmid: 17913305
references.citation: J Clin Microbiol. 2002 Aug;40(8):2823-7
references.pmid: 12149336
references.citation: Pediatrics. 2002 Jun;109(6):e88
references.pmid: 12042582
references.citation: J Virol. 2007 Sep;81(17):9386-95
references.pmid: 17567701
references.citation: Microbes Infect. 2006 Jun;8(7):1671-8
references.pmid: 16815726
references.citation: N Engl J Med. 1999 Sep 23;341(13):929-35
references.pmid: 10498487
references.citation: Vaccine. 2001 Aug 14;19(31):4429-33
references.pmid: 11483268
references.citation: J Paediatr Child Health. 2000 Aug;36(4):408-11
references.pmid: 10940185
references.citation: Int J Pharm. 2008 Feb 12;349(1-2):226-33
references.pmid: 17825506
references.citation: Annu Rev Microbiol. 2005;59:587-635
references.pmid: 16153180
references.citation: Genet Vaccines Ther. 2007 Apr 19;5:6
references.pmid: 17445254
references.citation: Biotechnol Lett. 2003 Jun;25(12):919-25
references.pmid: 12889824
references.citation: Biochem Biophys Res Commun. 2004 Jun 11;318(4):833-8
references.pmid: 15147946
references.citation: J Microbiol Immunol Infect. 2000 Dec;33(4):205-16
references.pmid: 11269363
references.citation: J Biomed Sci. 2000 Nov-Dec;7(6):523-8
references.pmid: 11060501
references.citation: J Clin Microbiol. 2009 Jul;47(7):2351-2
references.pmid: 19439545
references.citation: Pediatr Infect Dis J. 1987 Feb;6(2):206-8
references.pmid: 3562141
references.citation: Viral Immunol. 2008 Jun;21(2):215-24
references.pmid: 18419256
references.citation: J Gen Virol. 2005 May;86(Pt 5):1391-1401
references.pmid: 15831951
references.citation: Wkly Epidemiol Rec. 2008 May 9;83(19):169-70
references.pmid: 18472450
references.citation: Vaccine. 2003 May 1;21(16):1769-75
references.pmid: 12686092
references.citation: Vaccine. 2007 May 10;25(19):3731-41
references.pmid: 17350735
references.citation: Vaccine. 2001 Dec 12;20(5-6):895-904
references.pmid: 11738755
references.citation: Lancet. 1974 Jul 13;2(7872):112
references.pmid: 4136956
references.citation: Expert Rev Vaccines. 2009 Jan;8(1):5-8
references.pmid: 19093765
references.citation: Pediatr Infect Dis J. 1988 Jul;7(7):484-8
references.pmid: 2841639
references.citation: Microbiol Immunol. 2002;46(9):621-7
references.pmid: 12437029
references.citation: Expert Rev Vaccines. 2008 Aug;7(6):729-38
references.pmid: 18665772
references.citation: Vaccine. 2008 Mar 28;26(15):1855-62
references.pmid: 18329759
references.citation: World J Gastroenterol. 2006 Feb 14;12(6):921-7
references.pmid: 16521221